SANUWAVE HEALTH REPORTS RECORD 2018 FINANCIAL RESULTS FULL YEAR REVENUE INCREASED OVER 150% SUWANEE, GA

SANUWAVE HEALTH REPORTS RECORD 2018 FINANCIAL RESULTS

FULL YEAR REVENUE INCREASED OVER 150%

SUWANEE, GA, March 29, 2019 SANUWAVE Health, Inc. (OTCQB:

SNWV) will report financial

results for the year ended December 31, 2018 with the SEC on

Monday, April 1, 2019. The Company will also host a conference call

today, March 29, 2019 at 10:00 a.m. Eastern Time.

Highlights from 2018:

as President, Healthcare in May 2018.

insurance reimbursement tracking codes for Diabetic Foot Ulcer

(DFU) procedure using ESWT.

Signed Premier Shockwave Wound Care, Inc. as the

exclusive distributor of dermaPACE

for the Veteran's Administration

(VA), Indian Health Services (IHS) and Tribally-operated healthcare

shipments of the dermaPACE system in the U.S. Market in first

Dr. Perry Mayer, Medial Director and Principal at The Mayer

Institute ( TMI ) in Hamilton, Ontario, Canada to the

science advisory board.

Journal of Wound Care (JWC) published a peer review article on

SANUWAVE's 336 double blind study titled Diabetic foot

ulcer treatment with focused shockwave therapy: two multicenter

prospective, controlled, double-blinded, randomized phase III

15 countries to international distribution.

an agreement with NFS Leasing, Inc. to finance equipment

a Joint Venture with FKS, a JohnFK Medical company in Southeast

Asia, receiving upfront payments.

our patent portfolio as follows:

U.S. patent number US

10,053,376 entitled Acoustic Pressure Shock

Wave Devices and Methods for

U.S. patent number US

10,058,340 entitled Extracorporeal Pressure

Shock Wave Devices with

Multiple Reflectors and Methods for Using

European patent number

EP 2,984,280 entitled Apparatuses and Methods

for Generating Shock Waves

for Use in the Energy Industry

European patent number

EP 3,117,784 entitled Usage of

Intracorporeal Pressure Shock Waves in

at seven industry trade shows in 2018 and received a positive

Since receiving FDA clearance for the use of dermaPACE system for

treating DFUs on December 28, 2017, we have spent much of 2018

preparing for the full-on launch of dermaPACE in the US. Our

preparations were well laid out and achieved throughout 2018 and

included hiring the right people, gaining reimbursement tracking

codes to allow hospitals to get paid for using the system, and

establishing vested partners in channels and for financing the

purchase of devices for distribution. On top of this, the seeds we

have planted in the past led to record revenue and shipments in

2018 as well. Looking forward, the main focus in 2019 is about

dermaPACE placements, primarily in 6 key markets we have

prioritized based on research of the market. By achieving these

goals in 2019, we expect revenue growth beginning later this year

and continued growth ahead in the coming years, stated Kevin

Richardson, Chairman and CEO of the Company.

US dermaPACE system placements and 300 certified

the year with at least 10 million covered lives for insurance

2 - 3 domestic clinical studies.

3 - 4 new countries.

additional advisors to our scientific board.

other key senior management positions.

2018 was filled with achievements meant to prepare SANUWAVE for

rapid revenue growth beginning in 2019 and beyond. The stage is set

and it is now dependent on our ability to execute the well

developed plan of placing 100 dermaPACE devices in the US in 2019.

Our vision is to be viewed by the world as a diverse, compassionate

global family that provides positive impact on life and

environment, one shock at a time. The goal for SANUWAVE remains

unchanged and that is to have a dermaPACE device anywhere and

everywhere a DFU is treated.

2018 Financial Results (Unaudited)

for the year ended December 31, 2018 were $1,850,060, compared to

$738,527 for the same period in 2017, an increase of $1,111,533, or

151%. Revenue resulted primarily from sales in Europe and

Asia/Pacific of our orthoPACE devices and related applicators,

sales in the United States and Asia/Pacific of our dermaPACE

devices and related applicators and upfront license fee from our

Southeast Asia distribution agreement with FKS. The increase in

revenue for 2018 is primarily due to initial sales of dermaPACE

devices in the United States, an increase in sales of orthoPACE

devices in Asia/Pacific and the European Community, as compared to

the prior year, as well as higher sales of new

expenses for the year ended December 31, 2018 were $8,336,654,

compared to $4,321,003 for the same period in 2017, an increase of

$4,015,651, or 93%. Research and development expenses increased by

$371,307. The increase was due to an increase in salary and

benefits of $263,628 as a result of hiring and contracting for

temporary services and increased consulting expenses of $72,972

related to our insurance reimbursement strategy for the

commercialization of dermaPACE. General and administrative expenses

increased $3,646,081. The increase was due to an increase in salary

and benefits and recruitment fees related to new hires of

$1,062,594, increased legal costs of $196,845 associated with SEC

filings and patent issuance and maintenance, increased travel of

$156,986 related to tradeshows and joint venture with FKS, and

increased non-cash stock based compensation related to stock option

and stock warrants issued in 2018 to new and existing